Exenatide Suppliers & Bulk Manufacturers
Available Forms: injection (prefilled syringe)
Available Strengths: 5 mcg/1.2 mL, 10 mcg/2.4 mL
Reference Brands: Byetta (USA/EU), Bydureon (USA)
Category:
Diabetes
Exenatide is a GLP-1 (glucagon-like peptide-1) receptor agonist used to manage type 2 diabetes mellitus. It works by stimulating insulin secretion, inhibiting glucagon release, and slowing gastric emptying, which helps lower blood glucose levels. Exenatide is available as immediate-release injections (twice daily) and extended-release injections (once weekly). It may also support weight reduction in some patients.
Exenatide is available in injection (prefilled syringe)
and strengths such as 5 mcg/1.2 mL, 10 mcg/2.4 mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Exenatide is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Exenatide can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing